Plasma Proteome Profiling with Monoclonal Antibody Libraries: A Pilot Biomarker Analysis for Nanomedicine-Induced Complement Activation

János Szebeni, Zsóka Weiszhár, Zoltán Rozsnyay, Todd Martinsky, János Kádas, József Lázár, László Takács, István Kurucz

Arrayit Corporation Sunnyvale, USA.
Biosystems International Kft., Debrecen, Hungary.
Nanomedicine Research and Education Center, Semmelweis University, Budapest, Hungary.
Seroscience Ltd., Budapest, Hungary.

DOI: 10.4236/anp.2013.22022                

Abstract

Complement (C) activation-related hypersensitivity reactions (HSRs) represent an unsolved adverse immune effect of many i.v. administered “nanomedicines”, such as liposomal doxorubicin (Doxil/Caelyx). Because these pseudoallergic reactions can be severe or even lethal, it is an important clinical objective to find biomarkers for proneness for C activation by reactogenic nanoparticles that will allow the prediction of in vivo reactions by in vitro assays. With this goal in mind we identified a normal human blood donor who consistently showed high sensitivity to Caelyx-induced C activation in vitro, whose plasma (Caelyx sensitive plasma, CSP) was subjected to proteome profiling with a library of human plasma proteome specific mAbs. The chip (PlasmaScan-380^TM) contained 380 non redundant (with respect to epitopes) mAbs. The analysis revealed 8 proteins that were differentially represented in CSP in comparison with Caelyx-insensitive control plasma. These proteins were identified by mass spectrometry and Western blot analyses to represent factor H (decreased in CSP), factor H related protein, serum amyloid P component, fibronectin, complement component C4, Apo B100, prothrombin and alpha-2-HS glycoprotein (all increased in CSP). Some of these protein changes are consistent with proneness for increased C activation, suggesting the potential use of this method in the search for biomarkers for liposome-induced or other types of nanomedicine-induced HSRs.

Keywords

Hypersensitivity Reactions; Complement Factor H; Serum Amyloid P; Proteome Profiling; Biomarkers

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. Szebeni, “Complement Activation-Related Pseudoallergy: A New Class of Drug-Induced Immune Toxicity,”Toxicology, Vol. 216, No. 2-3, 2005, pp. 106-121.
[2]	J. Szebeni, “Hemocompatibility Testing for Nanomedicines and Biologicals: Predictive Assays for Complement Mediated Infusion Reactions,” European Journal of Na nomedicine, Vol. 4, No. 1, 2012, pp. 33-53.
[3]	J. Szebeni, “Complement Activation-Related Pseudoallergy Caused by Liposomes, Micellar Carriers of Intravenous Drugs and Radiocontrast Agents,” Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 18, No. 6, 2001, pp. 567-606. doi:10.1615/CritRevTherDrugCarrierSyst.v18.i6.50
[4]	J. Szebeni, “Complement Activation-Related Pseudoallergy: Mechanism of Anaphylactoid Reactions to Drug Carriers and Radiocontrast Agents,” 2004, pp. 399-440.
[5]	J. Szebeni, F. Muggia, G. Gabizon and Y. Barenholz, “Activation of Complement by Therapeutic Liposomes and Other Lipid Excipient-Based Therapeutic Products: Prediction and Prevention,” Advancerd Drug Delivery Reviews, Vol. 63, No. 12, 2011, pp. 1020-1030. doi:10.1016/j.addr.2011.06.017
[6]	D. Wang, M. Hincapie, M. Guergova-Kuras, J. Kadas, L. Takacs and B. L. Karger, “Antigen Identification and Characterization of Lung Cancer Specific Monoclonal Antibodies Produced by mAb Proteomics,” Journal of Proteome Research, Vol. 9, No. 4, 2010, pp. 1834-1842. doi:10.1021/pr900997z
[7]	M. Guergova-Kuras, I. Kurucz, W. Hempel, N. Tardieu, J. Kádas, C. Malderez-Bloes, A. Jullien, Y. Kieffer, M. Hincapie, A. Guttman, E. Csánky, B. Dezso, B. Karger, L. Takács, “Discovery of Lung Cancer Biomarkers by Profiling the Plasma Proteome with Monoclonal Antibody Libraries,” Molecular and Cellular Proteomics, Vol. 10, No. 12, 2011, Article ID: M111.010298.
[8]	E. Csanky, P. Olivova, E. Rajnavolgyi, W. Hempel, N. Tardieu, E. Katalin, A. Jullien, C. Malderez-Bloes, M. Kuras, M. X. Duval, L. Nagy, B. Scholtz, W. Hancock, B. Karger, A. Guttman and L. Takacs, “Monoclonal Antibody Proteomics: Discovery and Prevalidation of Chronic Obstructive Pulmonary Disease Biomarkers in a Single Step,” Electrophoresis, Vol. 28, No. 23, 2007, pp. 4401-4406. doi:10.1002/elps.200700256
[9]	R. D. C. Team, “R: A Language and Environment for Statistical Computing,” R Foundation for Statistical Computing, Vienna, 2010.
[10]	L. Turiák, O. Ozohanics, F. Marino, L. Drahos and K. Vékey, “Digestion Protocol for Small Protein Amounts for Nano-HPLC-MS(MS) Analysis,” Journal of Proteomics, Vol. 74, No. 7, 2011, pp. 942-947. doi:10.1016/j.jprot.2011.01.007
[11]	J. Szebeni, B. Baranyi, S. Savay, L. U. Lutz, E. Jeleza rova, R. Bunger and C. R. Alving, “The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil?),” Journal of Liposome Research, Vol. 10, No. 4, 2000, pp. 347-361. doi:10.3109/08982100009031112
[12]	J. Szebeni, P. Bed?cs, Z. Rozsnyay, Z. Weiszhár, R. Urbanics, L. Rosivall, R. Cohen, O. Garbuzenko, G. Báthori, M. Tóth, R. Bünger and Y. Barenholz, “Liposome-Induced Complement Activation and Related Cardiopulmonary Distress in Pigs: Factors Promoting Reactogenicity of Doxil and AmBisome,” Nanomedicine NBM, Vol. 8, No. 2, 2012, pp. 176-184. doi:10.1016/j.nano.2011.06.003
[13]	Y. Barenholz, “Doxil—The First FDA-Approved Nano Drug: From and Idea to Product,” In: D. Peer, Ed., Hand book of Harnessing Biomaterials in Nanomedicine, Pan Standford Publishing Pte. Ltd., Singapure, 2012, pp. 335-398.
[14]	ClinicalTrials, “ClinicalTrials.gov,” Vol. 2011.
[15]	D. S. Alberts and D. J. Garcia, “Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer,” Drugs, Vol. 54, No. 4, 1997, pp. 30-45. doi:10.2165/00003495-199700544-00007
[16]	A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N. M. Rafique, C. R. Alving and F. M. Muggia, “Complement Activation Following First Exposure to Pegylated Liposomal Doxorubicin (Doxil): Possible Role in Hypersensitivity Reactions,” Annals of Oncology, Vol. 14, No. 9, 2003, pp. 1430-1437.doi:10.1093/annonc/mdg374
[17]	A. A. Gabizon and F. M. Muggia, “Initial Clinical Evaluation of Pegylated Liposomal Doxorubicin in Solid Tumors. In: M. C. Woodle and S. G. Austin, Eds., Long Circulating Liposomes: Old Drugs, New Therapeutics, Landes Bioscience, Texas, 1998, pp. 155-174.
[18]	O. Lyass, B. Uziely, R. Ben-Yosef, D. Tzemach, N. I. Heshing, M. Lotem, G. Brufman and A. A. Gabizon, “Correlation of Toxicity with Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma,” Cancer, Vol. 89, No. 5, 2000, pp. 1037-1047. doi:10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
[19]	K. M. Skubitz, A. P. Skubitz, “Mechanism of Transient Dyspnea Induced by Pegylated-Liposomal Doxorubicin (Doxil),” Anticancer Drugs, Vol. 9, No. 1, 1998, pp. 45-50. doi:10.1097/00001813-199801000-00005
[20]	B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao, Z. Yehoshua, E. Libson, F. M. Muggia and A. Gabizon, “Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities during Two Complementary Phase I Studies,” Journal of Clinical Oncology, Vol. 13, No. 7, 1995, pp. 1777-1785.
[21]	Doxil, “Package Insert,” 2012. http://www.doxil.com
[22]	J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, R. Bunger, P. Laverman, J. M. Metselaar, G. Storm, A. Chanan-Khan, L. Liebes, F. M. Muggia, R. Cohen, Y. Barenholz and C. R. Alving, “Role of Complement Activation in Hypersensitivity Reactions to Doxil and HYNIC-PEG Liposomes: Experimental and Clinical Studies,” Journal of Liposome Research, Vol. 12, No. 1-2, 2002, pp. 165-172. doi:10.1081/LPR-120004790
[23]	J. Szebeni, L. Baranyi, S. Sávay, M. Bodó, J. Milosevits, C. R. Alving and R. Bünger, “Complement Activation-Related Cardiac Anaphylaxis in Pigs: Role of C5a Anaphylatoxin and Adenosine in Liposome-Induced Abnormalities in ECG and Heart Function,” American Jour nal of Physiology, Vol. 290, No. 3, 2006, pp. H1050-H1058.
[24]	S. M. Moghimi, I. Hamad, T. L. Andresen, K. J?rgensen and J. Szebeni, “Methylation of the Phosphate Oxygen Moiety of Phospholipid-methoxy(polyethylene glycol) Con jugate Prevents PEGylated Liposome-Mediated Comple ment Activation and Anaphylatoxin Production,” FASEB Journal, Vol. 20, No. 14, 2006, pp. 2591-2593. doi:10.1096/fj.06-6186fje
[25]	G. Milosevits, Z. Rozsnyay, G. T. Kozma, J. Milosevits, G. Tomory, H. Robotka, L. Rosivall, J. Szebeni, “Flow Cytometric Analysis of Supravesicular Structures in Do xorubicin-Containing Pegylated Liposomes,” Chemistry and Physics of Lipids, Vol. 165, No. 4, 2012, pp. 482-487. doi:10.1016/j.chemphyslip.2011.11.012
[26]	P. Lieberman, R. L. Siegle and G. Treadwell, “Radiocontrast Reactions,” Clinical Reviews in Allergy, Vol. 4, No. 2, 1986, pp. 229-245.
[27]	P. Lieberman, “Anaphylactoid Reactions to Radiocontrast Materia,” Clinical Reviews in Allergy, Vol. 9, No. 3-4, 1991, pp. 319-338.
[28]	K. Takeda, J. M. Thurman, S. Tomlinson, M. Okamoto, Y. Shiraishi, V. P. Ferreira, C. Cortes, M. K. Pangburn, V. M. Holers and E. W. Gelfand, “The Critical Role of Complement Alternative Pathway Regulator Factor H in Allergen-Induced Airway Hyperresponsiveness and Inflammation,” Journal of Immunology, Vol. 188, No. 2, 2012, pp. 661-667. doi:10.4049/jimmunol.1101813
[29]	A. Capriotti, G. Caracciolo, C. Cavaliere, C. Crescenzi, D. Pozzi, A. Lagana, “Shotgun proteomic analytical appro ach for studying proteins adsorbed onto liposome surface,” Analytical and Bioanalytical Chemistry, Vol. 401, No. 4, 2011, pp. 1195-1202. doi:10.1007/s00216-011-5188-8
[30]	S. M. Moghimi and J. Szebeni, “Stealth Liposomes and Long Circulating Nanoparticles: Critical Issues in Pharmacokinetics, Opsonization and Protein-Binding Properties,” Progress in Lipid Research, Vol. 42, No. 6, 2003, pp. 463-478.doi:10.1016/S0163-7827(03)00033-X
[31]	A. Heiss, T. Eckert, A. Aretz, W. Richtering, W. van Dorp, C. Sch?fer and W. Jahnen-Dechent, “Hierarchical Role of Fetuin-A and Acidic Serum Proteins in the Formation and Stabilization of Calcium Phosphate Particles,” Journal of Biological Chemistry, Vol. 283, No. 21, 2008, pp. 14815-14825. doi:10.1074/jbc.M709938200
[32]	L. Kalabay, L. Jakab, K. Cseh, T. Pozsony and L. A. Jakab, “Correlations between Serum Alpha 2-HS-glycopro tein Concentration and Conventional Laboratory Parameters in Systemic Lupus Erythematosus,” Acta Medica Hungarica, Vol. 47, No. 1-2, 1990, pp. 53-64.
[33]	U. Amara, D. Rittirsch, M. Flierl, U. Bruckner, A. Klos, F. Gebhard, J. D. Lambris and M. Huber-Lang, “Interaction between the Coagulation and Complement System,” Advances in Experimental Medicine and Biology, Vol. 632, 2008, pp. 68-76. doi:10.1007/978-0-387-78952-1_6
[34]	M. M. Markiewski, B. Nilsson, K. N. Ekdahl, T. E. Mollnes and J. D. Lambris, “Complement and coagulation: strangers or partners in crime?,” Trends in Immunology, Vol. 28, No. 4, 2007, pp. 184-192. doi:10.1016/j.it.2007.02.006
[35]	E. C. Lasser, J. Slivka, J. H. Lang, W. P. Kolb, S. G. Lyon, A. E. Hamblin and G. Nazareno, “Complement and Coagulation: Causative Considerations in Contrast Catastrophies,” American Journal of Roentgenology, Vol. 132, No. 2, 1979, pp. 171-176. doi:10.2214/ajr.132.2.171
[36]	M. Huber-Lang, J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, J. D. Lambris, R. L. Warner, M. A. Flierl, L. M. Hoesel, F. Gebhard, J. G. Younger, S. M. Drouin, R. A. Wetsel and P. A. Ward, “Generation of C5a in the Absence of C3: A New Complement Activation Pathway,” Nature Medicine, Vol. 12, No. 6, 2006, pp. 682-687.
[37]	M. J. Krisinger, V. Goebeler, Z. Lu, S. C. Meixner, T. Myles, E. L. Pryzdial and E. M. Conway, “Thrombin Generates Previously Unidentified C5 Products That Support the Terminal Complement Activation Pathway,” Blood, Vol. 120, No. 8, 2012, pp. 1717-1725.
[38]	P. C. Harpel, “Human Plasma Alpha2-macroglobulin. An Inhibitor of Plasma Kallikrein,” The Journal of Experimental Medicine, Vol. 132, No. 2, 1970, pp. 329-352. doi:10.1084/jem.132.2.329
[39]	G. J. O’Neill and B. Dupont, “Serum C4 Levels, Chido, Rodgers, and Allotypes of C4 Component of Complement,” Transplantation Proceedings, Vol. 11, No. 1, 1979, pp. 1102-1106.
[40]	Y. Yang, E. K. Chung, B. Zhou, C. A. Blanchong, C. Y. Yu, G. Füst, M. Kovács, A. Vatay, C. Szalai, I. Karádi and L. Varga, “Diversity in Intrinsic Strengths of the Human Complement System: Serum C4 Protein Concentrations Correlate with C4 Gene Size and Polygenic Variations, Hemolytic Activities, and Body Mass Index,” Journal of Immunology, Vol. 171, No. 5, 2003, pp. 2734-2745.
[41]	S. Marcovina and C. J. Packard, “Measurement and Meaning of Apolipoprotein AI and Apolipoprotein B Plasma Levels,” Journal of Internal Medicine, Vol. 259, No. 5, 2006, pp. 437-446. doi:10.1111/j.1365-2796.2006.01648.x